1/4
Export Ready

ERLOCIP 150MG

Sold by melizza lifescience · Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup · Rajkot, Gujarat, India

Price
Price on request
In stock
Inclusive of all taxes
Minimum order: 1 Centimetre

Export Snapshot

MOQ
1 Centimetre
Lead time
On request
Packaging
Standard export packaging
Shelf life / longevity
As per product specification
HS Code
On request
Origin
India
Port of dispatch
On request
Export markets served
Algeria flag DZ Andorra flag AD Anguilla flag AI Angola flag AO Argentina flag AR +47 others
Values shown are for melizza lifescience.
Compliance & Certifications
Suitable for

Importers · Distributors · Wholesalers

Know your supplier

melizza lifescience is a Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup based in Rajkot Gujarat India.

Rajkot Dispatch on request Verified seller
melizza lifescience logo

melizza lifescience

Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup · Rajkot, Gujarat, India

Registered address: Rajkot, India. Industry: Healthcare, Medical Supplies & Pharmaceuticals > Drugs & Pharmaceuticals.

Established
Not shared
Employees
–
GST
24GQFPM5460R1Z4
IEC code
GQFPM5460R
Export markets
Algeria flag DZ Andorra flag AD Anguilla flag AI Angola flag AO Argentina flag AR +47 others
GlobalLinker Member Since
Aug 2025
Turnover
Incorporation Type
On request
Verified Seller
Product details

What are the specifications of this product?

Overview

Product Name: Erlocip 150mg Tablet Generic Name: Erlotinib 150 mg Manufacturer: Cipla Ltd. Therapeutic Category: Oncology / Targeted Therapy (EGFR Tyrosine Kinase Inhibitor) Product Description: Erlocip 150mg contains Erlotinib, a targeted anti-cancer medicine classified as an EGFR tyrosine kinase inhibitor (EGFR-TKI). It is used for the treatment of certain lung cancers and pancreatic cancer, particularly in patients whose tumors have epidermal growth factor receptor (EGFR) mutations. Erlotinib works by blocking signals from the EGFR protein that promote cancer cell growth and division, thereby slowing or stopping tumor progression. Indications: • Non-Small Cell Lung Cancer (NSCLC): o First-line treatment in patients with EGFR mutations o Maintenance therapy after platinum-based chemotherapy o Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen • Pancreatic Cancer: o In combination with gemcitabine for locally advanced, unresectable, or metastatic disease

Product Description

Mechanism of Action:

• Erlotinib selectively inhibits the tyrosine kinase activity of the EGFR receptor.

• Prevents phosphorylation and downstream signaling, leading to inhibition of cancer cell proliferation and induction of apoptosis.


Dosage & Administration:

• 150 mg once daily on an empty stomach (at least 1 hour before or 2 hours after meals).

• For pancreatic cancer: 100 mg once daily (with gemcitabine).

• Dose adjustments may be required based on tolerance and side effects.


Key Benefits:

• Oral targeted therapy – no hospital infusion required.

• Effective in EGFR mutation–positive lung cancers.

• Can improve survival and quality of life in advanced cancers.


Packaging:

• Box / Blister pack of 30 tablets (150 mg each).


Storage:

• Store below 30°C, in a dry place.

• Protect from light and moisture.


Important Notes:

• For use under strict oncologist supervision only.

• Common side effects: rash, diarrhea, loss of appetite, fatigue.

• Smoking reduces drug effectiveness – patients should stop smoking.

• Liver and kidney function should be monitored during treatment.

• Not recommended in pregnancy or breastfeeding.


Melizza Lifescience

Description provided by melizza lifescience.

Specifications

Generic Name Erlotinib
Dosage Strength 150 mg per tablet
Formulation Tablet
Pharmacological Action EGFR tyrosine kinase inhibitor that blocks cancer cell proliferation and induces apoptosis
Therapeutic Area Oncology - Targeted Cancer Therapy
Indications Non-Small Cell Lung Cancer, Pancreatic Cancer
Recommended Dose 150 mg once daily for NSCLC, 100 mg daily with gemcitabine for pancreatic cancer
Route of Administration Oral
Storage Instructions Store below 30°C in dry place, protect from light and moisture
Manufacturer Cipla Ltd.
Packaging Details Box or blister pack containing 30 tablets
Contraindications Pregnancy and breastfeeding
Monitoring Requirements Liver and kidney function tests advised during therapy
Drug Interactions Smoking reduces effectiveness; monitor patient status closely

Use cases

Category Pharmaceuticals > Oncology Drugs > Targeted Therapy > EGFR Tyrosine Kinase Inhibitors
Primary application Wholesale, distribution, and international sourcing
Brand Not specified
Product type Product

Logistics & handling

Lead time On request
Packaging As per buyer requirement
Storage condition As recommended by supplier
Origin India
Form As listed by supplier

Commercials (this seller)

Minimum order 1 Centimetre
Lead time On request
Payment terms As per negotiated commercial agreement.
Checkout type enquiry
Buyer questions

Frequently asked by buyers

Common questions B2B buyers ask before sourcing ERLOCIP 150MG. Answers compiled from verified sellers' commercial terms and platform data.

Q: Can Erlocip 150mg be used as a first-line treatment for NSCLC?
A: Yes, Erlocip 150mg is indicated as a first-line treatment for patients with non-small cell lung cancer (NSCLC) who have confirmed EGFR mutations.
Q: What is the recommended dosage of Erlocip 150mg for pancreatic cancer?
A: For pancreatic cancer, Erlocip is administered at 100 mg once daily in combination with gemcitabine, differing from the 150 mg dosage used for NSCLC.
Q: Are there any special storage requirements for Erlocip 150mg tablets?
A: Yes, Erlocip tablets should be stored below 30°C in a dry place and protected from light and moisture to maintain stability.
Q: Is Erlocip 150mg suitable for patients who smoke?
A: Smoking has been shown to reduce the effectiveness of Erlocip; therefore, patients are advised to cease smoking during treatment.
Q: What monitoring is essential during Erlocip 150mg therapy?
A: Liver and kidney function should be closely monitored throughout treatment with Erlocip to detect any potential adverse effects.
Q: What common side effects should be anticipated with Erlocip 150mg?
A: Common side effects include rash, diarrhea, loss of appetite, and fatigue; patients should report any severe or persistent symptoms to their healthcare provider.
Question not answered? Ask sellers directly — typical response within 4 hours.

What similar products are available in this category?

Browse all in category
View all →
remtrex 2.5mg, 15mg,
remtrex 2.5mg, 15mg,
Price on request MOQ 1 Centimetre
View Product
altanib nova imatinib 400mg tablets
altanib nova imatinib 400mg tablets
Price on request MOQ 1 Centimetre
View Product
gemdronic 5mg
gemdronic 5mg
Price on request MOQ 1 Centimetre
View Product
gemdronic 5mg
gemdronic 5mg
Price on request MOQ 1 Centimetre
View Product
lucrin depot 3.75 mg / 11.25 mg injection
lucrin depot 3.75 mg / 11.25 mg injection
Price on request MOQ 1 Centimetre
View Product
truvada-tablets
truvada-tablets
Price on request MOQ 1 Centimetre
View Product
abstet 250mg tablet (abiraterone acetate (250mg))
abstet 250mg tablet (abiraterone acetate (250mg))
Price on request MOQ 1 Piece
View Product
capeta nova 500mg
capeta nova 500mg
Price on request MOQ 1 Centimetre
View Product
ERLOCIP 150MG
ERLOCIP 150MG
Price on request · MOQ 1Centimetre